Daniel Williamson
Child & Adolescent Psychiatry · Watertown, NYNPI 1396192407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 28.9% of the total. 2025 is the largest year on record at $1,217, 6.5 times the $188 reported in 2021. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$628
- Otsuka America Pharmaceutical, Inc.$398
- AbbVie$377
- E.r. Squibb & Sons, L.L.C.$243
- Johnson & Johnson$225
- plus $920 from 12 others
What the payments were for
- Food & beverage$3,87499%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $1,132 |
| Alkermes, Inc. | 35 | $628 |
| Otsuka America Pharmaceutical, Inc. | 19 | $398 |
| AbbVie | 18 | $377 |
| E.r. Squibb & Sons, L.L.C. | 15 | $243 |
| Johnson & Johnson | 10 | $225 |
| Teva Pharmaceuticals USA, Inc. | 11 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
| Supernus Pharmaceuticals, Inc. | 6 | $108 |
| Axsome Therapeutics, Inc. | 6 | $108 |
| Sunovion Pharmaceuticals Inc. | 5 | $86 |
| Corium, LLC | 5 | $72 |
| Biogen | 3 | $65 |
| Lundbeck LLC | 3 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Gilead | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$3,921 in reported general payments places this provider in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $20,313 |
| Vilazodone Hcl | 11 | $1,124 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $814 |
| Gabapentin | 20 | $515 |
| Buspirone Hcl | 40 | $451 |
| Clonazepam | 30 | $372 |
| Amitriptyline Hcl | 14 | $166 |
| Zolpidem Tartrate | 14 | $148 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $145 |
| Sertraline Hcl | 14 | $129 |
| Mirtazapine | 14 | $113 |
| Risperidone | 14 | $79 |
| Lithium Carbonate | 15 | $59 |
| Fluoxetine Hcl | 25 | $58 |
| Diazepam | 18 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,132 | $20,31312 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $12914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in Watertown
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Parinda ParikhWhite Plains$185K
- Jeffrey NewcornNew York$165K
- John MarinoCanandaigua$70K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Vijay PampanaMiddletown$19K
- Marc ReitmanHuntington$13K
- Marie CharlesBrooklyn$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.